Characterisation of vaping liquids used in vaping devices across four countries: results from an analysis of selected vaping liquids reported by users in the 2016 ITC Four Country Smoking and Vaping Survey

Brian Vincent Fix; Richard J OConnor; Maciej Lukasz Goniewicz; Noel L Leigh; Michael Cummings; Sara C Hitchman; Geoffrey T Fong; Georges El Nahas; David Hammond; Ann McNeill; Ron Borland; Bill King; Mary N Palumbo

Journal article

Characterisation of vaping liquids used in vaping devices across four countries: results from an analysis of selected vaping liquids reported by users in the 2016 ITC Four Country Smoking and Vaping Survey

Brian Vincent Fix, Richard J OConnor, Maciej Lukasz Goniewicz, Noel L Leigh, Michael Cummings, Sara C Hitchman, Geoffrey T Fong, Georges El Nahas, David Hammond, Ann McNeill, Ron Borland, Bill King, Mary N Palumbo

TOBACCO CONTROL | BMJ PUBLISHING GROUP | Published : 2021

DOI: 10.1136/tobaccocontrol-2020-056338

Download PDF

Abstract

OBJECTIVES: This study presents an analysis of vaping products (VPs) purchased in the USA, Canada, England and Australia and assesses whether differences in regulations were associated with differences in the chemical composition of the VPs. METHODS: April-September 2017, a total of 234 VP refill liquids and prefilled cartridges were purchased in convenience samples of retail locations in each country. Products were chosen from brands and styles most commonly reported by current VP users in the 2016 ITC Four Country Smoking and Vaping Survey. All products were tested for nicotine, tobacco-specific nitrosamines (TSNAs), minor tobacco alkaloids, organic acids and flavouring chemicals. RESULTS:..

View full abstract

University of Melbourne Researchers

Ron Borland Author Melbourne School of Psychological Sciences

Related Projects (1)

UNDERSTANDING THE IMPACTS OF VAPORISED NICOTINE PRODUCTS ON SMOKING IN AUSTRALIA

Vaporised nicotine products (e.g., e-cigarettes) are widely used in Australia, even though possession of the nicotine fluid without a permit..

Grants

Awarded by US National Cancer Institute

Awarded by Canadian Institutes of Health Research

Awarded by National Health and Medical Research Council of Australia

Awarded by National Cancer Institute (NCI)

Awarded by Center for Tobacco Products of the Food and Drug Administration

Funding Acknowledgements

This study was supported by grants from the US National Cancer Institute (P01 CA200512), the Canadian Institutes of Health Research (FDN-148477) and by the National Health and Medical Research Council of Australia (APP 1106451). GTF was supported by a Senior Investigator Award from the Ontario Institute for Cancer Research. NicoTAR shared resource is supported by grants from the National Cancer Institute (NCI) (P30CA016056), and the NCI and the Center for Tobacco Products of the Food and Drug Administration (U54CA228110).